| 产品详情 |
| Edit |   |
|---|
| Product Name | WM983A Viable Cells (1 x 10^6 cells) |
|---|
| Description | WM983A is a VGP human malignant metastatic melanoma cell line that features the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line is wild type for PTEN, N-RAS, c-KIT, and CDK4. This cell line was derived from the same patient as the cell lines WM983B, WM983B BR and WM983C.WM983A cells produce xenograft tumors when injected into immunocompromised mice. |
|---|
| Size | 1 mL |
|---|
| Concentration | 1x10^6 |
|---|
| Applications | The key applications of these cell lines include genetic studies, xenograft production, drug testing, and drug target discovery. These cell line models can be used in various biological assays, and for identifying critical target genes, and cell signaling pathways. |
|---|
| Other Names | Human Melanoma, patient derived tumor, tumor models, skin cancer, xenograft |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | WM983A-01-0001 |
|---|
| Price | |
|---|
| Order / More Info | WM983A Viable Cells (1 x 10^6 cells) from ROCKLAND IMMUNOCHEMICALS INC. |
|---|
| Product Specific References | Szaboet al. Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNβ secretion controlled differently by TLR3 and MDA5. Melanoma Res. (2012) 22:351-61. doi: 10.1097/CMR.0b013e328357076c. |
|---|
| 产品资料 |
|
|